Novartis to Acquire Regulus for $1.7 Billion with Potential Milestone Payoff

Novartis announces the acquisition of Regulus Therapeutics Inc. for $1.7 billion, including a potential additional $7.00 per share in cash through a contingent value right. The merger agreement is set to enhance Novartis' global development and commercial capabilities.